Broker notes, analysis and comments
To be resilient in an economic storm, a bank needs three things – low risk assets, strong capital and surplus deposits. Arbuthnot Banking Group Plc (LON:ARBB) has all three. At..
CentralNic Group PLC (LON:CNIC) announced several appointments that have strengthened the management team after seven acquisitions over the past two calendar years. We believe this investment in management should form..
Diurnal Group PLC (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently..
Chamberlin plc (LON:CMH) recent trading update revealed that trading is stalling in these challenging times. The company, however, is taking appropriate strategic actions. The group has been financially de-risked, and..
What’s new. This morning Purplebricks Group PLC (LON:PURP) has provided an “update regarding current trading and the potential impact of COVID-19 and Govt guidance on the UK housing market.” Key points..
DWF Group PLC (LON:DWF) has issued a trading update, indicating that its Commercial business has been hit by COVID-19, with International also not growing to our expectations. While we believe..
Epwin Group PLC (LON:EPWN) has announced that it will implement a controlled shut down of its operating facilities for a temporary period in response to the anticipated reduction in demand...
What’s new. After an encouraging seasonal increase in Purplebricks Group Plc (LON:PURP) instructions in January and February 2020, activity in recent days has slowed sharply and we see prospects for a..
Arix Bioscience PLC (LON:ARIX) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high risk-return profile of early-stage..
At the Hardman & Co Investor Forum presentation, RMDL summarised the investment opportunity as “RM Secured Direct Lending PLC (LON:RMDL) offers access to a diverse portfolio of secured loans with..
B-North aims to raise capital ahead of getting its banking licence (due spring 2020) and attacking the huge, profitable and poorly served SME lending market. B-North combines i) state-of-the-art technology..
Haydale Graphene Industries PLC (LON:HAYD) commercial traction is improving, medium-term financial issues have now been addressed, and the refocusing and re-orientating of the business with a major cost-saving programme is..
Allergy Therapeutics PLC (LON:AGY) is a long-established specialist in the prevention, diagnosis and treatment of allergies. Pollinex Quattro (PQ) is an ultra-short course subcutaneous allergy immunotherapy (AIT) platform, which continues..
The key Pantheon International (LON:PIN) results message was “more of the same”, including: i) market-beating core NAV growth (known given previous disclosures); ii) strong EBITDA growth in underlying companies; iii)..
2019 results were announced on 12 February. 90% of Primary Health Properties PLC (LON:PHP) income is backed by the UK or RoI governments. Occupancy consistently exceeds 99%. We are confident..
Diurnal Group PLC (LON:DNL) is a commercial-stage specialty pharmaceutical company focused on diseases of the endocrine system. Its two lead products are targeting rare conditions where medical need is currently..
Burford Capital Limited (LON:BUR) recently released its first-ever trading statement, covering cash activity in 2019. Group-wide commitments set a new record of $1.57bn, a 24% increase. Overall deployments were almost..
Initiation of our coverage was 16 March 2016 at 101.5p. In February 2018, the price was 215p and it stayed north of £2 for another year. In fiscal 2019, though,..
City of London Investment Group (LON:CLIG) has announced its interim results for 1H’20. Several of the key figures were announced in the January trading statement, so the main interest is..
Arix Bioscience PLC (LON:ARIX) is a listed global venture capital (VC) company that presents an opportunity for institutional and retail investors to participate in the high risk-return profile of early-stage..
